SHAPE-ENDO (Strategic Hormonal Approach & Prehabilitation in Endometrial Cancer): Prospective Observational Study for Metabolic and Surgical Optimization in Patients With Atypical Endometrial Hyperplasia or Early-stage Endometrial Cancer and BMI ≥40 kg/m2. (Phase 1)
Latest Information Update: 22 May 2026
At a glance
- Drugs Levonorgestrel (Primary) ; Semaglutide (Primary)
- Indications Endometrial hyperplasia; Obesity
- Focus Therapeutic Use
- Acronyms SHAPE-ENDO
Most Recent Events
- 09 Apr 2026 Planned End Date changed from 1 Dec 2026 to 1 Sep 2028.
- 09 Apr 2026 Planned primary completion date changed from 1 Jun 2026 to 1 May 2027.
- 09 Apr 2026 Planned initiation date changed from 1 May 2026 to 1 Sep 2026.